- Induction and consolidation therapy with carfilzomib, thalidomide, and low-dose dexamethasone (KTd) is effective with manageable toxicity in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM),
Why this matters
- Carfilzomib is currently approved for the treatment of relapsed and/or refractory multiple myeloma.
- This is the first study of KTd induction and consolidation in this setting.
- Phase 2 Carthadex study to investigate KTd induction and consolidation in 111 patients with transplant-eligible NDMM.
- Induction was followed by high-dose melphalan and autologous stem cell transplantation.
- 4 doses were studied; overall results are summarized.
- Funding: Onyx Pharmaceuticals, Inc.
- Responses after induction:
- 93% overall response rate (ORR).
- 65% very good partial response (VGPR) rate or better.
- 18% complete response (CR) rate or better.
- Responses after consolidation:
- 94% ORR.
- 86% VGPR rate or better.
- 63% CR rate or better.
- 83 months (95% CI, 83-not reached [NR]) median OS.
- 58 (95% CI, 45-67) months median PFS.
- No association between dose level/risk status and OS.
- 10% of patients experienced grade 3-4 hematological toxicity.
- The most common grade 3-4 nonhematological toxicities were:
- Infections: 11%.
- Respiratory disorders: 8%.
- Skin disorders: 9%.
- Vascular disorders: 9%
- Open-label study.